Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Phase 2

Completed

• Conditions: Dyslipidemia

• Registration Number: NCT00326326
• Lead Sponsor: Pfizer

Brief Summary

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-05-12
• Study First Submitted QC: 2006-05-12
• Study First Posted: 2006-05-16
• Study Start: 2006-07
• Study Completion: 2007-06
• Status Verified: 2009-05
• Last Update Submitted: 2009-05-06
• Last Update Posted: 2009-05-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

• HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
• Triglycerides between 150-500 mg/dL
• Fasting Plasma Glucose 140-240 mg/dL

Exclusion Criteria

• Known cardiovascular, carotid, or peripheral vascular disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
HDL-C Safety and Efficacy

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 Milwaukee, Wisconsin, United States